Market cap
$58.81B
52-week range70% up the range
$662.47$1072.33

argenx SE (ARGX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for ARGX, including 4 SEC filings, 2 press releases and news items and 2 M&A updates. The most recent was published Nov 9, 2026.

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

ARGX rankings

Price$947.40-40.89 (-4.14%)
2026-08-172026-11-17

Financial highlights

Full financials
Revenue, FY2025
$4.25B
Revenue growth
+88.6%
Net income, FY2025
$1.29B
Net margin
30.4%
Free cash flow, FY2025
$679.03M
Cash
$3.49B

For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.

News · 26 weeks47-40%
2026-05-24: 22026-05-31: 22026-06-07: 02026-06-14: 02026-06-21: 22026-06-28: 02026-07-05: 02026-07-12: 12026-07-19: 22026-07-26: 52026-08-02: 62026-08-09: 02026-08-16: 42026-08-23: 52026-08-30: 12026-09-06: 02026-09-13: 12026-09-20: 02026-09-27: 22026-10-04: 32026-10-11: 12026-10-18: 42026-10-25: 02026-11-01: 22026-11-08: 42026-11-15: 0
2026-05-242026-11-15
Mix2390d
  • SEC Filings8(35%)
  • Other7(30%)
  • M&A3(13%)
  • Analyst2(9%)
  • Earnings2(9%)
  • Leadership1(4%)
Activity · 52 weeks8448 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Our reporting on ARGX

Latest news

25 items

ARGX FAQ

11 questions
  • What does argenx SE do?
    argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with...
  • What is the latest news on ARGX?
    In the last 30 days Quantisnow tracked 10 wire items for ARGX: 4 SEC filings, 2 press releases and news items, 2 M&A updates and 1 earnings update. The most recent was published on November 9, 2026.
  • What is ARGX revenue?
    argenx SE (ARGX) reported $4.25B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 88.6% from the year before.
  • Is ARGX profitable?
    Yes. argenx SE earned $1.29B in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 30.4%.
  • How much cash and debt does ARGX have?
    argenx SE reported $3.49B in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does ARGX stock trade?
    argenx SE (ARGX) is listed on NASDAQ.
  • What sector and industry is ARGX in?
    argenx SE operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did argenx SE go public?
    argenx SE (ARGX) completed its IPO in 2017.
  • What are analysts saying about ARGX?
    Across the last 8 analyst actions on argenx SE, there were 2 upgrades and 4 downgrades. The most recent action was from UBS: Buy with a $1400.00 price target on 2026-08-26. Recent price targets range from $858.00 to $1400.00.
  • What companies are similar to ARGX?
    Notable peers in the same industry include SNY (Sanofi), AMGN (Amgen Inc.), ALNY (Alnylam Pharmaceuticals Inc.), IMVT (Immunovant Inc.), HRMY (Harmony Biosciences Holdings Inc.). Compare ARGX side-by-side with any of them on Quantisnow.
  • How can I track ARGX on Quantisnow?
    Quantisnow aggregates argenx SE's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARGX to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change